Clinical Study of Airway Stent Implantation in the Treatment of Patients with Malignant Central Airway Obstruction
Table 2
Log-rank analysis results of 98 MCAO patients after stent placement.
Feature
n
(95% CI) (month)
value
Gender
—
—
0.562
Male
74
9.97 (6.68–13.25)
—
Female
24
13.79 (6.24–21.33)
—
Age
—
—
0.809
>60 years old
72
11.59 (7.72–15.46)
—
≤60 years old
26
9.09 (4.64–13.55)
—
With hypertension
—
—
0.685
No
52
9.67 (5.53–13.81)
—
Yes
46
12.00 (7.49–16.51)
—
With diabetes
—
—
0.632
No
87
11.38 (7.98–14.78)
—
Yes
11
8.09 (1.48–14.70)
—
Primary disease
—
—
0.044
Lung cancer
53
8.28 (5.12–11.44)
—
Esophageal cancer
22
11.33 (4.24–18.43)
—
Other∗
23
20.58 (9.64–31.53)
—
ECOG PS score
—
—
0.021
0–2 points
80
12.35 (8.83–15.86)
—
3–4 points
18
3.85 (0.96–6.73)
—
Treatment after stent placement
—
—
0.371
No treatment
22
11.82 (3.09–20.55)
—
Chemotherapy
21
8.51 (4.01–13.00)
—
Radiotherapy
14
15.33 (3.58–27.09)
—
Chemotherapy
31
11.61 (6.57–16.64)
—
Only receive supportive care
7
5.00 (0.35–9.66)
—
Stent
—
—
<0.001
Trachea
46
15.23 (9.94–20.51)
—
Left main bronchus
19
4.95 (2.13–7.77)
—
Right main bronchus
21
8.63 (5.34–11.91)
—
Other†
8
1.25 (0.45–2.05)
—
Hb (g/L)
—
—
0.007
<110
34
5.48 (3.24–7.72)
—
≥110
64
14.16 (9.37–18.94)
—
ALB (g/L)
—
—
<0.001
<40
60
6.64 (4.53–8.75)
—
≥40
38
23.22 (13.25–33.20)
—
Feature
n
(95% CI) (month)
value
LDH (µg/L)
—
—
0.082
<250
68
12.21 (8.39–16.40)
—
≥250
30
5.51 (1.97–12.99)
—
∗Other diseases included airway stenosis, esophagotracheal fistula, lung infection, thyroid cancer, laryngeal cancer, tracheal space occupying, bronchial adenoid cystic carcinoma, mantle cell lymphoma. †Other diseases included right middle bronchus, left main bronchus + right main Bronchus, and right middle bronchus + right distal bronchi. Hb: hemoglobin; ALB: albumin; LDH: serum lactate dehydrogenase.
